{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T18:17:15Z","timestamp":1715969835616},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1007\/bf02561672","type":"journal-article","created":{"date-parts":[[2007,2,8]],"date-time":"2007-02-08T08:48:53Z","timestamp":1170924533000},"page":"S45-S51","source":"Crossref","is-referenced-by-count":9,"title":["Development of resistance and perspectives for future therapies against hepatitis B infections: Lessons to be learned from HIV"],"prefix":"10.1007","volume":"27","author":[{"given":"K.","family":"Deres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"R\u00fcbsamen-Waigmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02561672_CR1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000150565","volume":"40","author":"E. Jaeckel","year":"1997","unstructured":"Jaeckel, E., Manns, M. P.: Experience with lamivudine against hepatitis B virus. Intervirology 40 (1997) 322\u2013336.","journal-title":"Intervirology"},{"key":"BF02561672_CR2","unstructured":"Hepatitis overview. Clinica. Doc. No.: C00529354 (1997)."},{"key":"BF02561672_CR3","unstructured":"Market dynamics: global opportunities in hepatitis to 2010. Datamonitor Americas. New York (1998)."},{"key":"BF02561672_CR4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1086\/515696","volume":"178","author":"P. J. Coleman","year":"1998","unstructured":"Coleman, P. J., McQuillan, G. M., Moyer, L. A., Lambert, S. B., Margolis, H. S.: Incidence of hepatitis B virus infection in the United States, 1976\u20131994: estimates from the National Health and Nutrition Examination Surveys. J. Infect. Dis. 178 (1998) 954\u2013959.","journal-title":"J. Infect. Dis."},{"issue":"Suppl. 2","key":"BF02561672_CR5","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1136\/gut.38.Suppl_2.S39","volume":"38","author":"G. B. Yao","year":"1996","unstructured":"Yao, G. B.: Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 38 (Suppl. 2) (1996) S39-S42.","journal-title":"Gut"},{"issue":"Suppl. 1","key":"BF02561672_CR6","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/BF02042169","volume":"43","author":"M. A. Kane","year":"1998","unstructured":"Kane, M. A.: The global epidemiology of hepatitis B: Soz. Pr\u00e4ventivmed. 43 (Suppl. 1), (1998) S24-S26.","journal-title":"Pr\u00e4ventivmed."},{"key":"BF02561672_CR7","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","volume":"103","author":"F. E. Jongh de","year":"1992","unstructured":"de Jongh, F. E., Janssen, H. L., de Man, R. A., Hop, W. C., Schalm, S. W., van Blankenstein, M.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver (see comments). Gastroenterology 103 (1992) 1630\u20131635.","journal-title":"Gastroenterology"},{"key":"BF02561672_CR8","first-page":"165","volume-title":"Viral hepatitis","author":"R. H. Decker","year":"1993","unstructured":"Decker, R. H.: Diagnosis. In:Zuckerman, A. J., Thomas, H. C. (eds.): Viral hepatitis. Churchill Livingstone. Edinburgh 1993, pp. 165\u2013184."},{"key":"BF02561672_CR9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00001574-199611000-00011","volume":"12","author":"B. Rehermann","year":"1996","unstructured":"Rehermann, B., Manns, M. P.: Immunologic aspects of acute and chronic hepatitis B and C. Curr. Opin. Gastroenterol. 12 (1996) 554\u2013559.","journal-title":"Curr. Opin. Gastroenterol."},{"key":"BF02561672_CR10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","volume":"2","author":"B. Rehermann","year":"1996","unstructured":"Rehermann, B., Ferrari, C., Pasquinelli, C., Chisari, F.V.: The hepatitis-B virus persists for decades after patients recover from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Medicine 2 (1996) 1104\u20131108.","journal-title":"Nature Medicine"},{"issue":"Suppl. 3","key":"BF02561672_CR11","first-page":"13","volume":"3","author":"M. J. Koziel","year":"1998","unstructured":"Koziel, M. J.: The immunopathogenesis of HBV infection. Antiviral Ther. 3 (Suppl. 3) (1998) 13\u201324.","journal-title":"Antiviral Ther."},{"key":"BF02561672_CR12","unstructured":"Pharmaprojects, Doc. No.: PH029050 (1999)."},{"key":"BF02561672_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-0934(98)00172-4","volume":"78","author":"M. Trippler","year":"1999","unstructured":"Trippler, M., zum Buschenfelde, K. H. M., Gerken, G.: HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR. J. Virol. Methods 78 (1999) 129\u2013147.","journal-title":"J. Virol. Methods"},{"key":"BF02561672_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","volume":"13","author":"F. V. Chisari","year":"1995","unstructured":"Chisari, F. V., Ferrari, C.: Hepatitis-B virus immunopathogenesis. Annual Review of Immunology 13 (1995) 29\u201360.","journal-title":"Annual Review of Immunology"},{"key":"BF02561672_CR15","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1136\/gut.34.2_Suppl.S20","volume":"34","author":"C. Trepo","year":"1993","unstructured":"Trepo, C., Zoulim, F., Alonso, C., Petit M. A., Pichoud, C., Vivitski, L.: Diagnostic markers of viral hepatitis-B and hepatitis-C. Gut 34 (1993) S20-S25.","journal-title":"Gut"},{"key":"BF02561672_CR16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0168-8278(05)80632-4","volume":"21","author":"R. Muller","year":"1994","unstructured":"Muller, R., Samuel, D., Fassati, L. R., Benhamou, J. P., Bismuth, H., Alexander, G. J. M.: Eurohep consensus report on the management of liver transplantation for hepatitis-B virus infection. J. Hepatol. 21 (1994) 1140\u20131143.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1099-1654(1998100)8:4<223::AID-RMV229>3.0.CO;2-J","volume":"8","author":"A. R. Marques","year":"1998","unstructured":"Marques, A. R., Straus, S. E.: Advances in the treatment of chronic hepatitis B virus infection. Reviews in Medical Virology 8 (1998) 223\u2013234.","journal-title":"Reviews in Medical Virology"},{"key":"BF02561672_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728214.4.1.15","volume":"4","author":"F. F. Poordad","year":"1999","unstructured":"Poordad, F. F., Gish, R. G.: Evolving therapies for the treatment of viral hepatitis. Emerging Drugs 4 (1999) 15\u201335.","journal-title":"Emerging Drugs"},{"key":"BF02561672_CR19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000007532","volume":"59","author":"J. H. Hoofnagle","year":"1998","unstructured":"Hoofnagle, J. H.: Therapy of viral hepatitis. Digestion 59 (1998) 563\u2013578.","journal-title":"Digestion"},{"issue":"Suppl.","key":"BF02561672_CR20","first-page":"348A","volume":"28","author":"M. Prieto","year":"1998","unstructured":"Prieto, M., Cordoba, J., Rayon, J. M., Garcia-Herola, A., Berenguer, M., Carraseo D., Olaso, V., Mir, J., Berenguer, J.: Good response to lamivudine therapy in patients with de novo hepatitis B following orthotopic liver transplantation: a pilot study. Hepatology 28 (Suppl.) (1998) 348A.","journal-title":"Hepatology"},{"key":"BF02561672_CR21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-2008-1040517","volume":"9","author":"R. P. Perillo","year":"1989","unstructured":"Perillo, R. P.: Treatment of chronic hepatitis B with IFN: experience in western countries. Semin. Liver Dis. 9 (1989) 240\u2013241.","journal-title":"Semin. Liver Dis."},{"key":"BF02561672_CR22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0016-5085(84)90601-2","volume":"86","author":"J. H. Hoofnagle","year":"1984","unstructured":"Hoofnagle, J. H., Hanson, R. G., Minuk, G. Y., Pappas S. C., Schafer, D. F., Dusheiko, G. M., Straus, S. E., Popper, H., Jones, E. A.: Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86 (1984) 150\u2013157.","journal-title":"Gastroenterology"},{"key":"BF02561672_CR23","first-page":"506","volume":"15","author":"G. Y. Minul","year":"1992","unstructured":"Minul, G. Y., German, G. B., Bernstein, C., Benarroch, A., Gauthier, T., Sekla, L.: A piliot study of steroid withrawal followed by oral acyclovir in the treatment of chronic type-B hepatitis. Clin. Invest. Med.-Medicine Clinique et Experimentale 15 (1992) 506\u2013512.","journal-title":"Clin. Invest. Med.-Medicine Clinique et Experimentale"},{"key":"BF02561672_CR24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/364275d0","volume":"364","author":"C. Macilwain","year":"1993","unstructured":"Macilwain, C.: NIH, FDA seek lessons from hepatitis-B drug trial death. Nature 364 (1993) 275.","journal-title":"Nature"},{"key":"BF02561672_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.1994.03520010017006","volume":"272","author":"C. Marwick","year":"1994","unstructured":"Marwick, C.: NIH panel report of \u2018no flaws\u2019 in FIAU trial at variance with FDA report, new probe planned (news). JAMA 272 (1994) 9\u201311.","journal-title":"JAMA"},{"key":"BF02561672_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0168-8278(05)80387-3","volume":"21","author":"M. W. Fried","year":"1994","unstructured":"Fried, M. W., Fong, T. L., Swain, M. G., Park, Y., Beams, M. P., Banks, S. M., Hoofnagle, J. H., Dibisceglie, A. M.: Therapy of chronic hepatitis-B with a 6-month course of ribavirin. J. Hepatol. 21 (1994) 145\u2013150.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.510230101","volume":"23","author":"R. G. Gish","year":"1996","unstructured":"Gish, R. G., Lau, J. Y. N., Brooks, L., Fang, J. W. S., Steady, S. L., Imperial, J. C., Garciakennedy, R., Esquivel, C. O., Keeffe, E. B.: Ganciclovir treatment of hepatitis-B virus infection in liver-transplant recipients. Hepatology 23 (1996) 1\u20137.","journal-title":"Hepatology"},{"key":"BF02561672_CR28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00004836-199603000-00016","volume":"22","author":"B. S. Anand","year":"1996","unstructured":"Anand, B. S., Yoffe, B., Young, J. B.: Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patients. J. Clin. Gastroenterol. 22 (1996) 144\u2013146.","journal-title":"J. Clin. Gastroenterol."},{"key":"BF02561672_CR29","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(95)92367-5","volume":"346","author":"H. Nelson","year":"1995","unstructured":"Nelson, H.: FDA advised to license three anti-HIV agents (news). Lancet 346 (1995) 1358.","journal-title":"Lancet"},{"key":"BF02561672_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01880662","volume":"16","author":"J. Balzarini","year":"1994","unstructured":"Balzarini, J.: Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharmacy World and Science 16 (1994) 113\u2013126.","journal-title":"Pharmacy World and Science"},{"key":"BF02561672_CR31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF02974012","volume":"21","author":"J. H. Hong","year":"1998","unstructured":"Hong, J. H., Choi, Y., Chun, B. K., Lee, K., Chu, C. K.: Current status of anti-HBV chemotherapy. Archives of Pharmacal Research 21 (1998) 89\u2013105.","journal-title":"Archives of Pharmacal Research"},{"key":"BF02561672_CR32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1128\/AAC.39.7.1430","volume":"39","author":"A. Severini","year":"1995","unstructured":"Severini, A., Liu, X. Y., Wilson, J. S., Tyrrell, D. L.: Mechanism of inhibition of duck hepatitis B virus polymerase by(-)-beta-L-2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine. Antimicrob. Agents Chemother. 39 (1995) 1430\u20131435.","journal-title":"Antimicrob. Agents Chemother."},{"key":"BF02561672_CR33","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0006-2952(96)00562-X","volume":"52","author":"L. Cui","year":"1996","unstructured":"Cui, L., Schinazi, R. F., Gosselin, G., Imbach, J. L., Chu, C. K., Rando, R. F., Revankar, G. R., Sommadossi, J. P.: Effect of betaenantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatoxicity. Biochem. Pharmacol. 52 (1996) 1577\u20131584.","journal-title":"Biochem. Pharmacol."},{"key":"BF02561672_CR34","first-page":"57","volume":"6","author":"W. B. Parker","year":"1994","unstructured":"Parker, W. B., Cheng, Y. C.: Mitochondrial toxicity of antiviral nucleoside analogues. J. NIH Res. 6 (1994) 57\u201361.","journal-title":"J. NIH Res."},{"key":"BF02561672_CR35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/AAC.40.2.448","volume":"40","author":"F. Zoulim","year":"1996","unstructured":"Zoulim, F., Dannaoui, E., Borel, C., Hantz, O., Lin, T. S., Liu S.H., Trepo, C. Cheng, Y. C.: 2\u2032,3\u2032-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus resverse transcription and suppress viral DNA synthesis in hepatocytes, bothin vitro andin vivo. Antimicrob. Agens Chemother 40 (1996) 448\u2013453.","journal-title":"Antimicrob. Agens Chemother"},{"key":"BF02561672_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"C. L. Lai","year":"1998","unstructured":"Lai, C. L., Chien, R. N., Leung, N. W. Y., Chang, T. T., Guan, R., Tai, D.I., Ng K. Y., Wu, P. C., Dent, J. C., Barber, J., Stephenson, S. L., Gray, D. F.: A one-year trial of lamividine for chronic hepatitis B. N. Engl. J. Med. 339 (1998) 61\u201368.","journal-title":"N. Engl. J. Med."},{"key":"BF02561672_CR37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199512213332501","volume":"333","author":"J. L. Dienstag","year":"1995","unstructured":"Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., Rubin, M.: A prelinary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333 (1995) 1657\u20131661.","journal-title":"N. Engl. J. Med."},{"key":"BF02561672_CR38","unstructured":"Scrip, Doc. No.: S00622582 (1999)."},{"key":"BF02561672_CR39","doi-asserted-by":"crossref","first-page":"A1235","DOI":"10.1016\/S0016-5085(98)85010-5","volume":"114","author":"J. Dienstag","year":"1998","unstructured":"Dienstag, J., Schiff, E. R., Wright, T., Perrillo, R., Hann, H. W., Crowther, L., Woessner, M., Rubin, M., Brown, N., Group US Lamividine Investigator: Lamivudine treatment for one year in previously untreated US hepatitis B patients: histologic improvement and hepatitis B e antigen seroconversion. Gastroenterology 114 (1998) pA1235.","journal-title":"Gastroenterology"},{"key":"BF02561672_CR40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2893.1996.tb00098.x","volume":"3","author":"J. Main","year":"1996","unstructured":"Main, J., Brown, J. L., Howells, C., Galassini, R., Crossey, M., Karayiannis, P., Georgiou, P., Atkinson, G., Thomas, H. C.: A double blind, placebo controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Virol. Hepatitis 3 (1996) 211\u2013215.","journal-title":"J. Virol. Hepatitis"},{"key":"BF02561672_CR41","unstructured":"Scrip, Doc. No.: S00620466, (1999)."},{"key":"BF02561672_CR42","unstructured":"Scrip, Doc. No.: S00611502, (1999)."},{"key":"BF02561672_CR43","first-page":"1316","volume":"28","author":"R. J. C. Gilson","year":"1998","unstructured":"Gilson, R. J. C., Murray-Lyon, I. M., Nelson, M. R., Rice, S. J., Tedder, R. S., Murray, A., Jaffe, H. S., Weller, I. V. D.: Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology 28 (1998) 1316.","journal-title":"Hepatology"},{"key":"BF02561672_CR44","first-page":"A66","volume":"37","author":"X. Xiong","year":"1998","unstructured":"Xiong, X., Flores, C., Yang, H., Westland, C. E., Tolle, J. J., Gibbs, C. S.: Mutations in human hepatitis B virus polymerase associated with resistance to lamivudine and famiciclovir do not decrease sensitivity to adefovir. Antiviral Res. 37 (1998) pA66.","journal-title":"Antiviral Res."},{"issue":"Suppl. 1","key":"BF02561672_CR45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0168-8278(98)80636-3","volume":"28","author":"C. Gibbs","year":"1998","unstructured":"Gibbs, C., Flores, C., Yang, H., Westland, C., Toole, J., Xiong, X.: HBV polymerase mutations associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir. J. Hepatol. 28 (Suppl. 1) (1998) 111.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR46","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/hep.510280629","volume":"28","author":"X. F. Xiong","year":"1998","unstructured":"Xiong, X. F., Flores, C., Yang, H., Toole, J. J., Gibbs, C. S.: Mutations in hepatitis B DNA polymerase associated resistance to lamivudine do not confer resistance to adefovirin vitro. Hepatology 28 (1998) 1669\u20131673.","journal-title":"Hepatology"},{"key":"BF02561672_CR47","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0006-2952(99)00073-8","volume":"57","author":"L. Fu","year":"1999","unstructured":"Fu, L., Liu, S. H., Cheng, Y. C.: Sensitivity of L-(-)2\u2032,3\u2032-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem. Pharmacol. 57 (1999) 1351\u20131359.","journal-title":"Biochem. Pharmacol."},{"key":"BF02561672_CR48","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/00007890-199611270-00013","volume":"62","author":"V. G. Bain","year":"1996","unstructured":"Bain, V. G., Kneteman, N. M., Ma, M. M., Gutfreund, K., Shapiro, J. A. Fischer, K., Tipples, G., Lee, H., Jewell, L. D., Tyrrell, D. L.: Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62 (1996) 1456\u20131462.","journal-title":"Transplantation"},{"key":"BF02561672_CR49","first-page":"714","volume":"24","author":"G. A. Tipples","year":"1996","unstructured":"Tipples, G. A., Ma, M. M., Fischer, K. P., Bain, V. G., Knetemann, N. M., Tyrrell, D. L. J.: Mutation in HBV RNA-dependent DNA-polymerase confers resistance to lamivudinein vivo. Hepatology 24 (1996) 714\u2013717.","journal-title":"Hepatology"},{"key":"BF02561672_CR50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.510240339","volume":"24","author":"R. Ling","year":"1996","unstructured":"Ling, R., Mutimer, D., Ahmed, N., Boxall E. H., Elias, E., Dusheiko, G. M., Harrison, T. J.: Selection of mutations in the hepatitis-B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24 (1996) 711\u2013713.","journal-title":"Hepatology"},{"key":"BF02561672_CR51","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/hep.510270634","volume":"27","author":"K. Chayama","year":"1998","unstructured":"Chayama, K., Suzuki, Y., Kobayashi, M., Kobayashi, M., Tsubota, A., Hashimoto, M., Miyano, Y., Koike, H., Kobayashi, M., Koida, I., Arase, Y., Saitoh, S., Murashima, N., Ikeda, K., Kumada, H.: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 (1998) 1711\u20131716.","journal-title":"Hepatology"},{"key":"BF02561672_CR52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1086\/517819","volume":"177","author":"H. G. M. Niesters","year":"1998","unstructured":"Niesters, H. G. M., Honkoop, P., Haagsma, E. B., deMan, R. A., Schalm, S. W., Osterhaus, A. D. M. E.: Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177 (1998) 1382\u20131385.","journal-title":"J. Infect. Dis."},{"key":"BF02561672_CR53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/135965359900400101","volume":"4","author":"P.A. Cane","year":"1999","unstructured":"Cane, P.A., Mutimer, D., Ratcliffe, D., Cook, P., Beards, G., Elias, E., Pillay, D.: Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Ther. 4 (1999) 7\u201314.","journal-title":"Antiviral Ther."},{"key":"BF02561672_CR54","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","volume":"27","author":"M. I. Allen","year":"1998","unstructured":"Allen, M. I., Deslauriers, M., Andrews, C. W., Tipples, G. A., Walters, K. A., Tyrrell, D. L. J., Brown, N., Condreay, L. D.: Identification and characterization of mutations in hepatitis B virus resitant to lamivudine. Hepatology 27 (1998) 1670\u20131677.","journal-title":"Hepatology"},{"key":"BF02561672_CR55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1155\/1998\/617039","volume":"12","author":"E. M. Yoshida","year":"1998","unstructured":"Yoshida, E. M., Ma, M. M., Davis, J. E. Fischer, K. P., Kneteman, N. M., Erb, S. R., Tyrrell, D. L., Bain, V. G.: Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long term follow-up. Can. J. Gastroenterol. 12 (1998) 125\u2013129.","journal-title":"Can. J. Gastroenterol."},{"issue":"Suppl. 1","key":"BF02561672_CR56","first-page":"77","volume":"26","author":"R. A. Man De","year":"1997","unstructured":"De Man, R. A., Bartholomeusz, A., Locarnini, S., Niesters, H. G. M., Zondervan, P. E.: The occurrence of sequential viral mutations in a liver transplant recipient reinfected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance. J. Hepatol. 26 (Suppl. 1) (1997) 77.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR57","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0168-8278(98)80164-5","volume":"29","author":"R. A. deMan","year":"1998","unstructured":"deMan, R. A., Bartholomeusz, A. I., Niesters, H. G. M., Zondervan, P. E., Locarnini, S. A.: The sequential occurence of viral mutations in liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J. Hepatol. 29 (1998) 669\u2013675.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR58","first-page":"123","volume":"5","author":"A. Bartholomeusz","year":"1997","unstructured":"Bartholomeusz, A., Locarnini S.: Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. International Antiviral News 5 (1997) 123\u2013124.","journal-title":"International Antiviral News"},{"issue":"Suppl. 1","key":"BF02561672_CR59","first-page":"14","volume":"42","author":"S. Whalley","year":"1998","unstructured":"Whalley, S., Manolakopoulos, S., Brown, D., Davies, S., Ling, R., Harrison, T., Dusheiko, G.: Emergence of lamivudine resistant HBV is not always associated with HBeAg positive status or a high pretreatment viral load in patients with chronic infection. Gut 42 (Suppl. 1) (1998) 14.","journal-title":"Gut"},{"key":"BF02561672_CR60","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0168-8278(99)80204-9","volume":"30","author":"D. Mutimer","year":"1999","unstructured":"Mutimer, D., Pillay, D., Dragon, E., Tang, H., Ahmed, M., O'Donnell, K., Shaw, J., Burroughs, R., Rand, D., Cane, P., Martin, B., Buchan, S., Boxall, E., Barnat, S., Gutekunst, K., McMaster, P., Elias, E.: High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J. Hepatol. 30 (1999) 715\u2013721.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR61","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1099\/0022-1317-80-3-601","volume":"80","author":"R. Ling","year":"1999","unstructured":"Ling, R., Harrison, T. J.: Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J. Gen. Virol. 80 (Part 3) (1999) 601\u2013606.","journal-title":"J. Gen. Virol."},{"key":"BF02561672_CR62","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/hep.510290340","volume":"29","author":"S. K. Ono-Nita","year":"1999","unstructured":"Ono-Nita, S. K., Kato, N., Shiratori, Y., Masaki, T., Lan, K. H., Carrilho, F. J., Omata, M.: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study byin vitro full-length viral DNA transfection. Hepatology 29 (1999) 939\u2013945.","journal-title":"Hepatology"},{"key":"BF02561672_CR63","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0006-2952(98)00050-1","volume":"55","author":"L. Fu","year":"1998","unstructured":"Fu, L., Cheng, Y. C.: Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(\u2212)SddC (3TC) resistance. Biochem. Pharmacol. 55 (1998) 1567\u20131572.","journal-title":"Biochem. Pharmacol."},{"key":"BF02561672_CR64","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1128\/AAC.42.8.2128","volume":"42","author":"S. K. Ladner","year":"1998","unstructured":"Ladner, S. K., Miller, T. J., King, R. W.: The M539V polymerase variant in human hepatitis B virus demonstrates resistance to 2\u2032-deoxy-3\u2032-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42 (1998) 2128\u20132131.","journal-title":"Antimicrob. Agents Chemother."},{"key":"BF02561672_CR65","first-page":"65","volume":"9","author":"S. K. Ladner","year":"1998","unstructured":"Ladner, S. K., Miller, T. J., Otto, M. J., King, R. W.: The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antiviral Chemistry & Chemotherapy 9 (1998) 65\u201372.","journal-title":"Antiviral Chemistry & Chemotherapy"},{"issue":"Suppl. 1","key":"BF02561672_CR66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(98)80380-2","volume":"28","author":"J. Heathcote","year":"1998","unstructured":"Heathcote, J., Schalm, S. W., Cianciara, J., Farrell, G., Feinmann, V., Shermann, M., Dhillon, A. P., Moorat, A. E., Gray, D. F.: Lamivudine and intron: a combination treatment in patients with chronic hepatitis B infection. J. Hepatol. 28 (Suppl. 1) (1998) 43.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR67","unstructured":"Kim, J. W., Lee, M. Y., Chin, Y. J., Lim, C. Y., Song, I. H.: Interferon alpha versus interferon alpha and lamivudine in the treatment of chronic active hepatitis B. 8th International Symposium on Viral Hepatitis 121, 22 January 1998."},{"issue":"Suppl.","key":"BF02561672_CR68","first-page":"388A","volume":"28","author":"E. Schiff","year":"1998","unstructured":"Schiff, E., Karayalcin, S., Grimm, I., Perrillo, R., Dienstag, J., Husa, P., Schalm, S., Crowther, L., Sullivan, M., Woessner, M., McPhillips, P., Brown, N., Group International Lamivudine Investigator: A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28 (Suppl.) (1998) p388A.","journal-title":"Hepatology"},{"key":"BF02561672_CR69","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0168-8278(98)80338-3","volume":"28","author":"D. Mutimer","year":"1998","unstructured":"Mutimer, D., Naoumov, N., Honkoop, P., Marinos, G., Ahmed, M., deMan, R., McPhillips, P., Johnson, M., Williams, R., Elias, E., Schalm, S.: Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J. Hepatol. 28 (1998) 923\u2013929.","journal-title":"J. Hepatol."},{"key":"BF02561672_CR70","first-page":"295","volume":"78","author":"H. R\u00fcbsamen-Waigmann","year":"1999","unstructured":"R\u00fcbsamen-Waigmann, H.: Antiviral therapies: progress, resistance and trends. Nova Acta Leopoldina NF 78 (1999) 295\u2013312.","journal-title":"Nova Acta Leopoldina NF"},{"key":"BF02561672_CR71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/088922299311538","volume":"15","author":"E. M. Benson","year":"1999","unstructured":"Benson, E. M., Clarkson, J., Law, M., Marshall, P., Kelleher, A. D., Smith, D. E., Patou, G., Stewart, G. J., Cooper, D. A., Ffrench, R. A.: Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res. Hum. Retroviruses 15 (1999) 105\u2013113.","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"BF02561672_CR72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI117662","volume":"95","author":"A. Vitiello","year":"1995","unstructured":"Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., Lafond, R., Yuan, L. L., Chisari, F. V., Furze, J., Bartholomeuz, R., Chesnut, R. W.: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. 1. Induction of a primary cytotoxic T-lymphocyte response in humans. J. Clin. Invest. 95 (1995) 341\u2013349.","journal-title":"J. Clin. Invest."},{"key":"BF02561672_CR73","unstructured":"Pharmaprojects, Doc. No.: PH017693 (1999)."},{"issue":"Suppl.","key":"BF02561672_CR74","first-page":"490","volume":"28","author":"A. Alexopoulou","year":"1998","unstructured":"Alexopoulou, A., Zafiropoulou, R., Papakonstantinou, A., Hadziyannis, S. J.: Randomised trial in HBeAg negative patients with replicating virus with ganciclovir vs lamivudine in combination with interferon. Evaluation of long-term efficacy. Hepatology 28 (Suppl.) (1998) 490.","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BF02561672_CR75","first-page":"389","volume":"28","author":"N. A. Terrault","year":"1998","unstructured":"Terrault, N. A., Wright, T. L., Roberts, J. P., Ascher, N. L.: Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine versus HBIG monotherapy as hepatitis B virus prophylaxis in liver transplant recipients. Hepatology 28 (Suppl.) (1998) 389.","journal-title":"Hepatology"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02561672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02561672\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02561672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T21:28:59Z","timestamp":1707600539000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02561672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":75,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["BF02561672"],"URL":"https:\/\/doi.org\/10.1007\/bf02561672","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]}}}